For decades, a diagnosis of metastatic pancreatic cancer carried with it a quiet finality — the disease, driven in nine of ten cases by a single rogue genetic switch, has resisted nearly every therapeutic advance medicine could offer. Now, a once-daily pill called daraxonrasib has doubled median survival in patients who had exhausted all other options, not by overwhelming the body with toxicity, but by binding to the very molecular machinery that tells cancer cells to keep dividing. It is not a cure, but in a disease where months are everything, it represents something oncology has rarely been
Daraxonrasib doubles survival in advanced pancreatic cancer, offering new hope
Pancreatic cancer patients with metastatic disease who have exhausted standard chemotherapy options now have access to a treatment that extends median survival and improves quality of life.
Time measured in months that patients did not have before
Mark
Why does KRAS matter so much in pancreatic cancer? What makes it different from other cancer genes?
Mimi
KRAS is the master switch. It tells cells when to grow and divide. When it mutates, that switch gets stuck in the "on" position. The cancer cells don't just grow—they grow relentlessly, and they ignore the normal signals that would tell them to stop. That's why pancreatic cancer is so aggressive.
Mark
And daraxonrasib just turns the switch off?
Mimi
Not exactly. It glues the switch in place so it can't send signals downstream. The cancer cells still exist, but they can't communicate the instruction to divide. It's a different mechanism than chemotherapy, which is why the side effects are so much lighter.
Mark
The survival numbers—6.7 months to 13.2 months—that's significant, but it's still not long. Why is this considered a breakthrough?
Mimi
Because for patients who have already failed chemotherapy, there was nothing. Zero options. They were watching the clock. Now they have time. And that time comes without the bone-crushing fatigue and neuropathy that chemotherapy causes. It's not just about the months—it's about what you can do with them.
Mark
Who can actually get this drug right now?
Mimi
Patients with metastatic disease who have already tried other treatments and have no other effective options. The expanded access program is narrow by design. But once FDA approval comes, that will change. There are patients waiting who could benefit immediately.
Mark
What happens next? Is this the end of the story?
Mimi
No. This is the beginning. Trials are starting to test whether daraxonrasib works earlier—maybe right after surgery, or combined with other drugs. And there are other KRAS inhibitors in development. The real breakthrough will be when we can use these drugs strategically, in combination, tailored to each patient's specific mutations.
O Pulso
- Pancreatic cancer's near-universal KRAS mutation has made it one of oncology's most stubborn adversaries, leaving patients after failed chemotherapy with almost no remaining options.
- Daraxonrasib broke that impasse in clinical trials, extending median survival from 6.7 to 13.2 months — a doubling that is reshaping how specialists and patients think about what is possible.
- Unlike the chemotherapy regimens it follows, the drug's side effects are manageable, offering patients not just more time but a meaningfully better quality of life during that time.
- Since May 2026, the drug has been available through an expanded access program before full FDA approval, with UT Southwestern among the approved sites — though eligibility requirements and detailed case reviews create real barriers for some patients.
- Multiple ongoing trials are now testing daraxonrasib earlier in treatment, in combination therapies, and as a potential first-line option, signaling that this drug may be the opening move in a broader transformation of pancreatic cancer care.
For decades, a diagnosis of metastatic pancreatic cancer carried with it a quiet finality — the disease, driven in nine of ten cases by a single rogue genetic switch, has resisted nearly every therapeutic advance medicine could offer. Now, a once-daily pill called daraxonrasib has doubled median survival in patients who had exhausted all other options, not by overwhelming the body with toxicity, but by binding to the very molecular machinery that tells cancer cells to keep dividing. It is not a cure, but in a disease where months are everything, it represents something oncology has rarely been able to offer pancreatic cancer patients: a reason for measured hope.
Pancreatic cancer has long carried a particular cruelty: nine out of ten cases are driven by a mutation in the KRAS gene that locks a cellular growth switch permanently on, and most patients are diagnosed only after the disease has already spread. Standard chemotherapy can slow progression, but at a severe cost to the body — and when tumors eventually resist those drugs, the options narrow to almost nothing.
Daraxonrasib has changed that calculus. In clinical trials, this once-daily pill doubled median survival for patients with metastatic pancreatic ductal adenocarcinoma whose prior chemotherapy had stopped working — from 6.7 months to 13.2 months. The drug belongs to a new class called RAS inhibitors, binding to mutated KRAS proteins like molecular glue and cutting off the growth signals that drive tumor expansion. It can target more than twenty different KRAS mutations, and its side effects — rash, diarrhea, nausea — are far more manageable than the systemic toll of traditional chemotherapy.
As of May 2026, daraxonrasib became available through an expanded access program, allowing patients with no remaining options to receive the treatment ahead of formal FDA approval. UT Southwestern's Harold C. Simmons Comprehensive Cancer Center is among the approved sites. The eligibility criteria are strict and the paperwork substantial, but the program exists precisely for this kind of moment — when waiting for full approval could cost patients the very time the drug is meant to provide.
Several clinical trials are now underway to test the drug earlier in treatment: post-surgery to prevent recurrence, in combination with other therapies, and potentially as a first-line option. For oncologists fielding daily questions about the drug, daraxonrasib represents something genuinely rare in this disease — an advance that extends survival without dismantling the body in the process. It is a foothold, not a finish line, but it marks the beginning of a shift from managing inevitable decline to prolonging life with dignity.
Pancreatic cancer has long been one of the cruelest diagnoses in oncology. Nine out of every ten cases involve a specific genetic sabotage: a mutation in the KRAS gene that locks a cellular growth switch permanently in the "on" position. The cancer cells divide without restraint, and by the time most patients are diagnosed, the disease has already spread. Standard chemotherapy—gemcitabine, nab-paclitaxel, FOLFIRINOX—can slow the progression, but the toll on the body is severe: exhaustion, immune collapse, nerve damage, relentless nausea. For patients whose tumors eventually resist these drugs, the options narrow to almost nothing.
Then came daraxonrasib. In clinical trials, this once-daily pill doubled the median survival time for patients with metastatic pancreatic ductal adenocarcinoma whose previous chemotherapy had stopped working. The improvement was stark: from 6.7 months to 13.2 months. That is not a cure, but it is a reprieve—time measured in months that patients and their families did not have before.
The drug works through a mechanism that sounds almost elegant in its simplicity. Daraxonrasib belongs to a new class called RAS inhibitors. It binds to mutated KRAS proteins like molecular glue, jamming up their ability to send growth signals downstream. The cancer cells, starved of their marching orders, stop dividing. The drug can target more than twenty different KRAS mutations, which matters because the genetic landscape of pancreatic cancer is varied. And unlike the chemotherapy regimens it follows, daraxonrasib is gentler. The side effects—rash, diarrhea, nausea, mouth sores—are manageable compared to the systemic devastation of traditional cancer drugs.
As of May 2026, the drug became available through an expanded access program, a pathway that allows patients with no other options to receive experimental treatments before formal FDA approval. Eligible patients are those with metastatic disease who have already tried other therapies and have nowhere else to turn. UT Southwestern's Harold C. Simmons Comprehensive Cancer Center is among the approved treatment sites. The criteria are strict—patients must meet specific medical conditions, and each case requires detailed paperwork—but the program exists precisely for moments like this, when a new therapy shows promise and waiting for full approval could mean the difference between months of life and none at all.
The broader landscape of pancreatic cancer treatment is shifting. Surgery remains the best option when the tumor can be removed before it spreads, but recurrence is common. For patients whose cancer cannot be surgically removed, the goal becomes extending both quantity and quality of life. Several clinical trials are now underway to test whether daraxonrasib might work even earlier in treatment—perhaps right after surgery to prevent recurrence, or combined with other therapies for patients with limited metastatic spread. Other trials are exploring whether the drug could work as a first-line treatment on its own, without chemotherapy. The National Pancreas Foundation has recognized UT Southwestern as an Academic and Clinical Center of Excellence, a designation that reflects the institution's commitment to bringing these emerging treatments to patients as quickly as possible.
For oncologists and patients alike, the early results have generated genuine momentum. Specialists report fielding questions about daraxonrasib daily. The drug represents something that has been rare in pancreatic cancer treatment: a genuine advance that extends survival without crushing the body in the process. It is not the final answer—pancreatic cancer remains one of the most difficult cancers to treat—but it is a foothold. More trials are coming. More drugs targeting KRAS mutations are in development. The future of pancreatic cancer care will likely involve combinations of these targeted therapies, radiation, and surgery, tailored to each patient's specific tumor genetics. For now, daraxonrasib marks the beginning of a shift from managing inevitable decline to actually prolonging life with dignity.
Citações Notáveis
This drug is the start of more breakthroughs to come, which will give more patients with pancreatic cancer a longer, higher quality of life.— UT Southwestern oncology specialists
Quer a matéria completa?
Leia o original em News-Medical ↗
Health & Medicine